Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

GL Capital-led consortium to buy SciClone Pharma

A GL Capital-led investor group have announced the acquisition of SciClone Pharmaceuticals Inc. PE Hub reported that the deal is valued at about $605 million. Other participants in the buyer consortium include CDH Investments and Ascendent Capital Partners. SciClone is a specialty pharmaceutical company with a product portfolio in oncology, infectious diseases and cardiovascular disorders.


PE Deals,private equity deals,pharmaceuticals,private equity investment,financial buyer,private equity firms,GL Capital